Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 285-292

  Ryan, Etchison ^a   Blake, A Jacobson ^a   Benoit, A ^a   David, M Ferguson ^a   Robert, A Kratzke ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

9 aminoacridine derivative; Catalytic inhibitor; Small cell lung cancer; Topoisomerase II

Indexed keywords

AMINOACRIDINE DERIVATIVE; CASPASE 3; CASPASE 7; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL STRAIN H417; CELL STRAIN H6; CELL STRAIN H69; CELL STRAIN H82; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; UPREGULATION;

AMINOACRIDINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; CISPLATIN; DNA TOPOISOMERASES, TYPE II; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PROTO-ONCOGENE PROTEINS C-AKT; SMALL CELL LUNG CARCINOMA; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84879555723     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9854-2     Document Type: Article

References (41)

1. Gazdar AF, Bunn PA Jr, Minna JD, Baylin SB (1985) Origin of human small cell lung cancer. Science 229(4714):679-680 [cited2012Feb2]
2. Oberg K, Hellman P, Kwekkeboom D, Jelic S (2010) Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(5):220-222 [cited2012Feb2]
3. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011. CA Cancer J Clin 61(4):212-236 [cited2012Jan30]
4. Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(4):379-392 [cited2012Feb2]
5. Schneider BJ (2008) Management of recurrent small cell lung cancer. J Natl Compr Canc Netw 6(3):323-331 [cited2012Feb2]
6. Govindan R, Page N, Morgensztern D, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539-4544 [cited2012Feb2]
7. Graille M, Cladière L, Durand D, et al. (2008) Crystal structure of an intact type II DNA topoisomerase: insights into DNA transfer mechanisms. Structure 16(3):360-370 [cited2011Mar6]
8. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3(6):430-440 [cited2011Feb16]
9. Walker JV, Nitiss JL (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 20(4):570-589 [cited2011Feb9]
10. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28(20):8154-8160 [cited2012Jan26]
11. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 1994;34191-218.[cited2012Jan26]
12. Chene P, Rudloff J, Schoepfer J, et al. (2009) Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol 9(1):1 [cited2011Feb21]
13. Kaufmann SH (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400(1-3):195-211 [cited2011Apr6]
14. Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17(5):421-433 [cited2011Mar6]
15. Deweese JE, Osheroff N (2009) The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 37(3):738
16. Wilstermann AM, Osheroff N (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Current Topics in Medicinal Chemistry 3(3):321-338
17. McClendon AK, Osheroff N (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat Res Fundam Mol Mech Mutagen 623(1-2):83-97
18. Azarova AM, Lyu YL, Lin CP, et al. (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci 104(26):11014
19. Degrassi F, Fiore M, Palitti F (2004) Chromosomal aberrations and genomic instability induced by topoisomerase-targeted antitumour drugs. Curr Med Chem Anticancer Agents 4(4):317-325 [cited2011Feb9]
20. Larsen AK, Escargueil AE, Skladanowski A (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther 99(2):167-181
21. Goodell JR, Ougolkov AV, Hiasa H, et al. (2008) Acridine-Based Agents with Topoisomerase II Activity Inhibit Pancreatic Cancer Cell Proliferation and Induce Apoptosis. J Med Chem 51(2):179-182
22. Oppegard LM, Ougolkov AV, Luchini DN, et al. (2009) Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Eur J Pharmacol 602(2-3):223-229 [cited2011Feb7]
23. Akimitsu N, Kamura K, Toné S, et al. (2003) Induction of apoptosis by depletion of DNA topoisomerase II [alpha] in mammalian cells. Biochem Biophys Res Commun 307(2):301-307
24. Mizushima N (2007) Autophagy: process and function. Genes Dev 21(22):2861-2873 [cited2011Apr17]
25. Moscat J, Diaz-Meco MT (2009) p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137(6):1001-1004 [cited2012Mar1]
26. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72(1):29-39 [cited2012Jan26]
27. Newman RA, Kondo Y, Yokoyama T, et al. (2007) Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 6(4):354-364 [cited2012Jan26]
28. Guo C, Gasparian AV, Zhuang Z, et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 28(8):1151-1161 [cited2011Mar6]
29. Denny WA (2002) Acridine derivatives as chemotherapeutic agents. Curr Med Chem 9(18):1655-1665 [cited2011Feb16]
30. René B, Fossé P, Khélifa T, Jacquemin-Sablon A, Bailly C (1997) Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1′ substitute on the aniline nucleus. Bull Cancer 84(10):941-948 [cited2011Apr6]
31. Goodell JR, Madhok AA, Hiasa H, Ferguson DM (2006) Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity. Bioorg Med Chem 14(16):5467-5480 [cited2011Feb9]
32. Adams A (2002) Crystal structures of acridines complexed with nucleic acids. Curr Med Chem 9(18):1667-1675 [cited2012Mar6]
33. Wilstermann AM, Bender RP, Godfrey M, et al. (2007) Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 46(28):8217-8225 [cited2012Mar6]
34. Osheroff N (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochemistry 28(15):6157-6160 [cited2012Mar6]
35. Wilstermann AM, Osheroff N (2001) Positioning the 3′-DNA terminus for topoisomerase II-mediated religation. J Biol Chem 276(21):17727-17731 [cited2012Mar6]
36. Smith MA, Rubinstein L, Anderson JR, et al. (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 17(2):569-577 [cited2012Mar6]
37. Oizumi S, Isobe H, Ogura S, et al. (2002) Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res 22(6C):4029-4037 [cited2011Feb9]
38. Khélifa T, Beck WT (1999) Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol Pharmacol 55(3):548
39. Dartsch DC, Schaefer A, Boldt S, Kolch W, Marquardt H (2002) Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis 7(6):537-548 [cited2012Mar6]
40. Raza A, Jacobson BA, Benoit A, et al. Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis[Internet]. Investigational New Drugs. 2011;[cited2011Dec19] Available from: http://www.springerlink.com/index/10.1007/s10637-011-9720-7
41. Mathew R, Karp CM, Beaudoin B, et al. (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137(6):1062-1075 [cited2012Mar1]